Legend Announces FDA clearance of IND application on CAR-T immuno-cell therapy for the Treatment of Multiple … – PR Newswire (press release)
|
Legend Announces FDA clearance of IND application on CAR–T immuno-cell therapy for the Treatment of Multiple …
PR Newswire (press release) LCAR-B38M (JNJ-68284528) is an autologous CAR–T therapy that targets B cell Maturation Antigen (BCMA), a molecule expressed on the surface of mature B lymphocytes and malignant plasma cells. The investigational therapy expresses an identical CAR … Janssen (JNJ) Announces Initiation of Phase 1b/2 Clinical Development Program Evaluating JNJ-68284528 CAR–T … |
